| Autor: |
Giulia Lombardo, Maria Antonietta Nettis, Caitlin Hastings, Zuzanna Zajkowska, Nicole Mariani, Naghmeh Nikkheslat, Courtney Worrell, Daniela Enache, Anna McLaughlin, Melisa Kose, Anna Bogdanova, Luca Sforzini, Anthony J. Cleare, Allan H. Young, Paola Dazzan, Valeria Mondelli, Carmine M. Pariante |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Brain, Behavior, & Immunity - Health, Vol 26, Iss , Pp 100561- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3546 |
| DOI: |
10.1016/j.bbih.2022.100561 |
| Popis: |
Background: Inflammation is a well-known risk factor for depression. Specifically, patients who do not respond to antidepressant treatment show higher levels of inflammatory biomarkers compared with responders. Thus, several studies have investigated the efficacy of anti-inflammatory add-on treatment in this population. However, major depressive disorder is more prevalent in females than in males, with sex differences present in antidepressant treatment response and in immune system regulation. To explore sex differences in inflammatory profiles and treatment responses, we investigated a cohort of patients with treatment resistant depression (TRD), for which they received an adjunctive, anti-inflammatory treatment with minocycline – the Minocycline in Depression (MINDEP) study. Methods: The MINDEP study is a 4-week double-blind, randomised, placebo-controlled clinical trial (stratified by sex) with 39 TRD participants, which demonstrated the efficacy of minocycline, an antibiotic with anti-inflammatory properties, in TRD patients with major depressive disorder (MDD) and evidence of low-grade inflammation measured with C-reactive protein (CRP) ≥ 3 mg/L. In these secondary analyses, we investigated the differential effects of minocycline in females (N = 22, 10 randomised to minocycline and 12 randomised to placebo) and in males (N = 17, 8 randomised to minocycline and 9 randomised to placebo) on changes in depressive symptoms (Δ- Hamilton Rating Scale for Depression (HAMD)-17), taking also into consideration CRP levels (CRP ≥3 mg/L vs. CRP |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
